 AN OPEN LABEL, RANDOMIZED, CROSSOVER STUDY TO ESTIMATE THE PHARMACOKINETICS AND EVALUATE THE SAFETY FOLLOWING A SINGLE DOSE OF AZITHROMYCIN 2G EXTENDED-RELEASE POWDER FOR ORAL SUSPENSION WITH A 3-DAY DOSING REGIMEN OF AZITHROMYCIN 500MG TABLET IN CHINESE HEALTHY MALE SUBJECTS: 